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Conclusion: The obtained sequences may be target genes
transactivated by PS1TP2 protein among which some
genes coding proteins involved in cell cycle regulation,
metabolism, immunity and cell apoptosis. This ﬁnding
brought some clues for studying the biological functions
of PS1TP2.
PP-106 Study of the association of hepatitis B
surface antigen and HLA with hepatocellular
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Introduction: Primary liver cancer accounts for only
1 2% of malignant tumors found at autopsy in western
countries. However, in some parts of Africa and Asia it
may account for up to 20 30% of all types of malignancy.
The high frequency of HBsAg positivity in individuals with
Hepatocellular Carcinoma (HCC) strongly suggests that
chronic HBV infection may contribute in some way towards
the development of 1ry liver cell carcinoma. Although HCC is
probably caused by one or more environmental carcinogens,
a hereditary predisposition to the tumor has not been
excluded.
Aim: Determine the incidence of HBsAg carriers patients
suffering from primary HCC and detect the association
between primary HCC and HLA.
Subjects and Methods: The material consisted of twenty
patients diagnosed as HCC based on Ultrasonographic ex-
amination and by Histopathology. Laboratory investigations;
liver biopsy, HBsAg, Anti-HBcAg (IgM) and HLA typing using
lymphocyte microcytotoxicity technique.
Results: The 20 studied cases were negative for HBcAb IgM
and 10 patients were positive for HBsAg. HLA typing revealed
signiﬁcant rise of HLA-A9, HLA-B5 among HCC patients. HLA-
A9 was signiﬁcantly increased in HBsAg positive and negative
cases. HLA-B5 was signiﬁcantly increased in HBsAg positive
cases only while HLA-B8 was signiﬁcantly increased in HBsAg
negative cases only.
In cases with mixed hepatic cirrhosis and Schistosomal
hepatic ﬁbrosis which were negative for HBsAg showed
signiﬁcant increase in HLA-A9.
Conclusions:
1. Signiﬁcant association of HBsAg positivity in patients
with HCC.
2. Signiﬁcant association of HLA-A9 and HLA-B5 with HCC.
3. HLA-A9 in patients mixed cirrhosis and Schistosomal
hepatic ﬁbrosis may be predisposing to HCC.
PP-107 Lentivirus mediated shRNA interference
targeting DR1 and CP region of HBV genome
stably inhibits viral replication in vitro
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RNAi is a potential tool for antiviral therapy. However,
plasmid-based shRNA and chemically synthetic siRNA are
ineffective in treating viral infection due to limited
transfection efﬁciency and short half-life. Thus, non-
replicating recombinant viral vectors, in particular lentiviral
DNA which can integrate into host genome, may represent
effective means in antiviral treatment. In order to study
the kinetics of gene silencing, it is desirable to suppress
genes in a regulated fashion. Such regulated RNAi system
can provide a way to express shRNA only when needed or
only in certain cells. Traditional anti-HBV drugs, such as
nucleoside analogues and interferon-a, are only partially
effective in reducing viral loads.
Here we applied the regulated lentiviral delivery system
to investigate the suppressive effect of siRNA on HBV.
We compared two expression systems, a DNA-based vector
(pSuper) under H1 promoter and the lentiviral vector, to
deliver siRNA targeting the direct repeat 1 (DR1) region,
the core promoter (CP) region or the reverse transcriptase
(RT) of HBV genome. First, we designed and constructed
shRNA into the pSuper vector and assessed the effect on
HBV replication in HepG2.2.15 cells. We found that the
shRNA targeting DR1 region (1826nt-1845nt) or the CP region
(1775nt-1795nt) signiﬁcantly suppressed HBV replication,
while shRNA targeting RT only had moderate effect. We
subsequently cloned shRNA cassettes targeting DR1 region
and CP region into the lentiviral vector, respectively.
Recombinant lentiviruses were transduced into HepG2.2.15
cells with 95% efﬁcacy as evidenced by ﬂuorescence
microscopy, resulting in great reduction at both mRNA
and protein levels which were maintained to 96h post-
transduction.
We are currently constructing the tetracycline operator
system into the lentiviral vector to generate a tetracycline
based-regulated RNAi system. This conditional RNAi system
will provide a promising tool to analyze siRNA-mediated
anti-HBV therapy.
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Aim: To explore the prevalence of transfusion transmitted
virus (TTV) infection in patients with viral liver diseases.
Methods: TTV DNA in serum from all enrolled patients with
viral liver disease (VLD) was detected with PCR method.
Anti-HAV, HBV-marker, anti-HCV, anti-HDV and anti-HEV
markers were also tested by ELISA. HBVDNA, HCVRNA and
HGV RNA were detected by PCR and RT-PCR method.
Results: The prevalence rate of TTV infection in VLD
patients was 14.7% (43/292). Of all the patients,
the percentage of TTV infection was 5.0% (2/40),
15.9% (29/182), 31.6% (6/19) and 11.8% (6/51), respectively
in patients with acute hepatitis (AH), chronic hepatitis (CH),
severe hepatitis (SH) and liver cirrhosis (LC); in which the
rate of TTV infection with SH predominated (p < 0.001).
Of all the 43 patients with positive TTV in serum,
5 (11.6%) cases were infected with TTV alone, 38 (88.4%)
patients were super-infected with more than one hepatitis
virus (HV). The double infection rate was signiﬁcantly higher
than the single infection rate (p < 0.01). In the group
infected with TTV, there were 2 AH cases (4.7%), 29 CH
cases (67.4%), 6 SH cases (14.0%) and 6 LC cases (14.0%), and
in which CH predominated (p < 0.01). In AH group, 2 cases
infected with TTV, 1 with TTV only, another one was super-
infected with other HV. In CH group (29), 3 with TTV single
infection, 26 with TTV super-infection. In SH group, 1 was
with TTV single infection, 5 with TTV super-infected. In
LC group, all patients were TTV super-infected. In the group
infected with TTV only, most patients had the symptoms of
CH (60%). In the group super-infected with HV, most patients
were super-infected with HBV (89.5%, 34/38). The super-
infection group was composed of AH, CH, SH and LC (2.6%,
68.4%, 13.2%, and 15.8% respectively).
Conclusions: TTV infection is common in patients with viral
liver disease. TTV is frequently super-infected with other
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HV, especially HBV and HCV, and it seems to be related to the
pathogenicity of cirrhosis and fulminant hepatic failure.
PP-109 Usefulness of the serum concentrations of
TIMP-1 and TIMP-2 for predicting liver ﬁbrosis in
patients with chronic hepatitis B
R.T. Gao1, C.L. Zhu1 *, Y. Li1, Z.H. Zhao1. 1Department
of Infectious Disease, Anhui Provincial Hospital, Anhui
Medical University, Hefei, China
Objectives: We determined whether serum concentration
of TIMP-1 and TIMP-2 are related to the progress of liver
ﬁbrosis in patients with chronic hepatitis B (CHB).
Methods: Commercially available ELISA were used to
study circulating values of TIMP-1 and TIMP-2 in
CHB patients (n = 159) and 20 healthy controls. TIMP-1
and TIMP-2 expressions in the liver were detected
by immunohistochemical staining, then analyzed the
correlation between the levels of hepatic expression
and serum concentration of them. Hepatic histology was
evaluated, and quantiﬁed the stage of ﬁbrosis by using the
Hepatitis-Activity-Index (HAI) according to Ishak et al.
Results: The serum concentration of TIMP-1 or TMIP-2
positively correlated with their expression in the liver
of CHB patients, and both of them were higher in
the patients than those in the healthy controls, and
which had a signiﬁcant difference (P < 0.05). The serum
concentrations of TIMP-1 and TIMP-2 increased signiﬁcantly
with development of ﬁbrosis and had positive correlations
with HAI (r = 0.51, P < 0.01; r = 0.42, P < 0.01), whereas serum
ALT wasn’t related to ﬁbrosis or HAI.
Conclusions: Regular determinations of both TIMP-1 and
TIMP-2 in CHB patients may be used as indicators of
increasing ﬁbrosis.
Figure 1. Correlation between TIMP-1 and -2 expressions in
the liver and their concentration in the serum of patients
with CHB.
Table 1. The serum concentration of TIMP-1 and -2 in CHB patients with
different stages of ﬁbrosis
TIMP-1 (mg/L) TIMP-2 (mg/L) ALT (IU/L)
S0 84.32±18.53 52.34±24.21 45.37±9.31
S1 109.32±14.67 108.96±12.56 105.54±8.59
S2 135.65±22.95 111.47±25.32 676.4±202.35
S3 181.05±39.44 178.28±17.76 432.2±273.88
S4 279.91±61.83 255.54±110.02 75.7±29.80
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Introduction: Hepatitis B virus infection is recognized as
a major public health problem causing acute, persistant
or chronic liver infection. In Egypt, hepatitis B virus
infection is considered to be endemic. The attack rate of
hepatitis B was estimated to reach 8.9/10,000 in Alexandria.
Schistosomiasis is considered the major health problem in
Egypt. 12 14 million people are infected with Schistosoma
mansoni.
When Schistosomal and non-Schistosomal patients were
exposed to HBV, they were found to be equally susceptible,
however follow-up studies claimed that the ﬁrst group of
patients tend to exhibit hepatitis B antigenemia for longer
periods than the second group and this may hugely increase
the reservoir of carriers.
Aim: Determine the prevalence of HBsAg carriers,
demonstration of routes of antigen excretion and its
presence in liver sections and the prevalent subtype.
Subjects and Methods: Forty carriers of the hepatitis B
surface antigen were selected from 539 cases of
Schistosomal hepatic ﬁbrosis:
A. Detection of HBsAg in patients sera, Saliva, Urine and
Stools & Anti-HBcAg IgM.
B. Demonstration of HBsAg in infected hepatocytes.
C. Subtyping of HBsAg using the counter immuno-
electrophoresis.
Results:
• Hepatitis B surface antigen carriers was7.42%, Anti-HBsAg
IgM was negative.
• 5% of the salivary samples were HBsAg positive, while 50%
of the Urine and Stool were HBsAg positive.
• Urine and Saliva positivity ran parallel.
• Stool samples positive for HBsAg were all positive for
occult blood.
• Subtyping of the HBsAg for showed the “ay” subspeciﬁcity
which is considered the constant type of North Africa.
Conclusions:
• Screening of Schistosomal patients for the HBs antigen is
of importance as they represent a highly disseminating
source of infection.
• “ay” is the predominant subtype of HBs Ag.
• Disinfection of secretions and excretions of HBsAg positive
patients and their utensils is essential.
PP-111 Optimal threshold: baseline serum hepatitis B
virus DNA and alanine transaminase levels
predict the 2-year on-treatment virological
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Aims: To evaluate the predictive value of baseline levels of
HBVDNA and ALT for the long term efﬁcacy of lamivudine
treatment for patients with chronic hepatitis B and
determine the optimal cut off values of baseline levels
of HBVDNA and ALT.
Methods: A total of 163 HBeAg-positive chronic hepatitis B
patients receiving LAM treatment were recruited into the
present study. Logistic regression analysis was performed
to screen independent predictors of 2-year on-treatment
virological response among the baseline parameters. The
ROC curve was used to evaluate the predictive value of
these independent predictors. The accuracy of prediction
was assessed using area under curve (AUC) and optimal cut
off values were determined through maximizing Youden’s
index.
Results: After 2 years of LAM treatment, HBVDNA was
undetectable in 114 (69.9%) patients and LAM related
resistance mutation was detectable in 45 (27.6%) patients.
Logistic regression analysis indicated the baseline levels
of ALT and HBVDNA were the independent predictors
